Arvest Bank Trust Division Has $1.84 Million Stake in Bristol-Myers Squibb (NYSE:BMY)

Arvest Bank Trust Division reduced its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 2.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 32,453 shares of the biopharmaceutical company’s stock after selling 867 shares during the quarter. Arvest Bank Trust Division’s holdings in Bristol-Myers Squibb were worth $1,836,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of BMY. Fairway Wealth LLC bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $28,000. Comprehensive Financial Planning Inc. PA acquired a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $34,000. Westend Capital Management LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $38,000. Tacita Capital Inc bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $39,000. Finally, M Holdings Securities Inc. bought a new stake in Bristol-Myers Squibb during the 4th quarter worth $39,000. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on BMY shares. Truist Financial lifted their price target on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. UBS Group decreased their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research report on Friday, April 11th. Cantor Fitzgerald raised their price target on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. The Goldman Sachs Group restated a “neutral” rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Finally, Citigroup upped their price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $57.67.

Bristol-Myers Squibb Stock Performance

NYSE BMY opened at $49.33 on Thursday. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The company has a market cap of $100.37 billion, a P/E ratio of -11.16, a PEG ratio of 2.07 and a beta of 0.41. The company has a fifty day simple moving average of $57.24 and a 200 day simple moving average of $56.68. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Sell-side analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 5.03%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -56.11%.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,823 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was purchased at an average cost of $54.84 per share, with a total value of $99,973.32. Following the transaction, the executive vice president now directly owns 63,932 shares in the company, valued at $3,506,030.88. This trade represents a 2.94 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.07% of the stock is currently owned by company insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.